Anthem Biosciences Limited (ANTHEM) — Board Meeting

📢 Key Event
Board approved unaudited financial results for Q1 FY2027 and ESOPS share issuance.

🔄 What Changed
Profit after tax rose to ₹1,020.09 crores (standalone) and ₹1,199.41 crores (consolidated) from prior quarter, with consolidated revenue at ₹4,431.07 crores.

💡 Investor Takeaway
The company delivered strong quarterly profits and expanded its capital through ESOPS, signaling growth momentum and shareholder-friendly actions.

Anthem Biosciences announced the outcome of its board meeting held on July 21, 2026, where it approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The results show revenue of ₹4,124.42 crores (standalone) and ₹4,431.07 crores (consolidated), with profit after tax of ₹1,020.09 crores and ₹1,199.41 crores respectively. The board also approved the issuance of 1,670,909 fully paid equity shares under ESOPS 2024. The financials were reviewed by the Audit Committee and statutory auditors, with no material misstatements identified.

📄 View Original Announcement (PDF)

📊 Stock Analysis — ANTHEM ✨ Ask AI About This